176 related articles for article (PubMed ID: 35899612)
1. Inhalable Formulation Based on Lipid-Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast.
Craparo EF; Cabibbo M; Scialabba C; Giammona G; Cavallaro G
Biomacromolecules; 2022 Aug; 23(8):3439-3451. PubMed ID: 35899612
[TBL] [Abstract][Full Text] [Related]
2. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin-based inhaled therapy for potential treatment of COPD-related inflammation: production and characterization of aerosolizable nano into micro (NiM) particles.
Craparo EF; Cabibbo M; Scialabba C; Casula L; Lai F; Cavallaro G
Biomater Sci; 2024 Jan; 12(2):387-401. PubMed ID: 37997957
[TBL] [Abstract][Full Text] [Related]
4. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
[TBL] [Abstract][Full Text] [Related]
5. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
6. Microfluidic fabrication and characterization of Sorafenib-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery.
Tahir N; Madni A; Li W; Correia A; Khan MM; Rahim MA; Santos HA
Int J Pharm; 2020 May; 581():119275. PubMed ID: 32229283
[TBL] [Abstract][Full Text] [Related]
7. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
8. Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance of cancer cells.
Yuan Y; Chiba P; Cai T; Callaghan R; Bai L; Cole SPC; Cai Y
Oncol Rep; 2018 Aug; 40(2):1055-1063. PubMed ID: 29901161
[TBL] [Abstract][Full Text] [Related]
9. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
10. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
[TBL] [Abstract][Full Text] [Related]
11. Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy.
Tahir N; Madni A; Correia A; Rehman M; Balasubramanian V; Khan MM; Santos HA
Int J Nanomedicine; 2019; 14():4961-4974. PubMed ID: 31308666
[No Abstract] [Full Text] [Related]
12. Stealth lipid polymer hybrid nanoparticles loaded with rutin for effective brain delivery - comparative study with the gold standard (Tween 80): optimization, characterization and biodistribution.
Ishak RAH; Mostafa NM; Kamel AO
Drug Deliv; 2017 Nov; 24(1):1874-1890. PubMed ID: 29191047
[TBL] [Abstract][Full Text] [Related]
13. Design and characterization of emulsified spray dried alginate microparticles as a carrier for the dually acting drug roflumilast.
Mahmoud AA; Elkasabgy NA; Abdelkhalek AA
Eur J Pharm Sci; 2018 Sep; 122():64-76. PubMed ID: 29928985
[TBL] [Abstract][Full Text] [Related]
14. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
Conte G; Costabile G; Baldassi D; Rondelli V; Bassi R; Colombo D; Linardos G; Fiscarelli EV; Sorrentino R; Miro A; Quaglia F; Brocca P; d'Angelo I; Merkel OM; Ungaro F
ACS Appl Mater Interfaces; 2022 Feb; 14(6):7565-7578. PubMed ID: 35107987
[TBL] [Abstract][Full Text] [Related]
15. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
16. Development of a new formulation of roflumilast for pulmonary drug delivery to treat inflammatory lung conditions.
Suzuki ÉY; Amaro MI; de Almeida GS; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2018 Oct; 550(1-2):89-99. PubMed ID: 30130605
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist.
Milara J; Morell A; Ballester B; Sanz C; Freire J; Qian X; Alonso-Garcia M; Morcillo E; Cortijo J
Respir Res; 2015 Feb; 16(1):12. PubMed ID: 25652132
[TBL] [Abstract][Full Text] [Related]
18. Investigating the effectiveness of Difluprednate-Loaded core-shell lipid-polymeric hybrid nanoparticles for ocular delivery.
Kaviarasi B; Rajana N; Pooja YS; Rajalakshmi AN; Singh SB; Mehra NK
Int J Pharm; 2023 Jun; 640():123006. PubMed ID: 37137420
[TBL] [Abstract][Full Text] [Related]
19. Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids.
Craparo EF; Teresi G; Bondi' ML; Licciardi M; Cavallaro G
Int J Pharm; 2011 Mar; 406(1-2):135-44. PubMed ID: 21185363
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
